KRRO
Korro Bio, Inc.
$12.05
-6.52%
2026-05-08
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Key Fundamentals
Forward P/E
-1.62
EPS (TTM)
$-11.68
ROE
-87.8%
Profit Margin
0.0%
Debt/Equity
35.85
Price/Book
2.29
Beta
2.44
Market Cap
$180.4M
Avg Volume (10D)
79K
Recent Breakout Signals
No recent breakout signals detected for KRRO.
Recent Price Range (60 Days)
60D High
$15.51
60D Low
$9.90
Avg Volume
181K
Latest Close
$12.05
Get breakout alerts for KRRO
Sign up for Breakout Scanner to receive daily notifications when KRRO triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Korro Bio, Inc. (KRRO) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors KRRO daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. KRRO operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.